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Abstract: The immunogenicity of Pasteurella haemolytica serotypes was investigated in an experimental animal model. Rabbits were
immunized with bacterins and leukotoxins of selected serotypes of P. haemolytica, and the IgG level and antileukotoxin activities of
immune sera were measured. The highest IgG levels against A1, A2, A7 and T4 antigens were detected in rabbits receiving polyvalent
combined (bacterin plus leukotoxin) immunogens. Monovalent combined immunogens induced high antibody titers against
homologous serotypes, but low titers against heterologous serotypes. Serotype A1 and A7 were found to be more antigenic than
A2 and T4. The highest antileukotoxin activity in monovalent groups was detected in A1 and A7 antisera. Immune sera were used
for the protection of mice challenged with homologous and heterologous serotypes. Antisera to polyvalent combined immunogens
protected 83-100% of mice against A1, A7 and T4 challenge, and 50% of mice against A2 challenge. The lowest protection (1633%) was seen in serotype A6-infected mice, as heterologous challenge. In conclusion, marked differences were found in the
immunogenicity of P. haemolytica serotypes and limited protection was observed against heterologous serotypes.
Key Words: Pasteurella haemolytica, serotype, immunity, immunogenicity.

Pasteurella haemolytica Serotiplerinin Immunojenitelerinin Deneysel Modeller ile
Değerlendirilmesi
Özet: Pasteurella haemolytica serotiplerinin immunojeniteleri deneysel hayvan modelinde incelendi. Tavşanlar belirli P. haemolytica
serotiplerinin bakterinleri ve leukotoksinleri ile bağışıklandıktan sonra, bağışık serumların IgG düzeyleri ve antileukotoksin aktiviteleri
incelendi. A1, A2, A7 ve T4 antijenlerine karşı en yüksek IgG düzeyi, polivalan kombine immunojen verilen tavşanlarda saptandı.
Monovalan kombine immunojenler, homolog serotipe karşı yüksek, heterolog serotipe karşı düşük titrede antikor oluşturdular.
Serotip A1 ve A7, A2 ve T4'e göre daha antijenik bulundu. Monovalan gruplarda, en yüksek antileukotoksin aktivitesi A1 ve A7
antiserumlarında saptandı. İmmun serumlar, homolog ve heterolog serotiplerle infekte edilen farelerde pasif koruma amacıyla
kullanıldı. Polivalan kombine immunojene karşı immun serum, farelerin %83-100'ünü A1, A7 ve T4 infeksiyonuna, %50'sini A2
infeksiyonuna karşı korudu. En düşük düzeyde koruma (%16-33), heterolog serotip olarak kullanılan A6 ile infekte farelerde
görüldü. Sonuçta, P.haemolytica serotiplerinin immunojeniteleri arasında belirgin farklılıklar olduğu ve heterolog serotipe karşı yeterli
koruma sağlanamadığı kanısına varıldı.
Anahtar Sözcükler: Pasteurella haemolytica, serotip, bağışıklık, immunojenite.

Introduction
Pneumonia is a major cause of economic losses in the
sheep industry, and Pasteurella haemolytica is the
infectious agent most frequently associated with
pathologic damage of the ovine respiratory tract (1). P.
haemolytica is divided into two biotypes based on
carbohydrate fermentation patterns and 16 serotypes
based on surface antigens (2). All serotypes can be
involved in disease. However, there is a wide variation in
the prevalence of individual serotypes isolated from

pneumonic pasteurellosis (3,4). P. haemolytica possesses
several components that may function as virulence
factors. Foremost among these is leukotoxin which is
secreted during the logarithmic growth phase and is
lethal to ovine leukocytes and lymphocytes (5,6). The
capsular polysaccharide, as another virulence factor, also
impairs the ability of neutrophils to ingest and kill P.
haemolytica (7).

P. haemolytica has numerous potential immunogens,
such as capsular polysaccharide, LPS, OMPs, fimbriae,
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iron-regulated proteins and leukotoxin (7). Although a
number of bacterins, live and extract vaccines containing
such potential immunogens have been developed, their
efficacy in field trials has been variable (7-11). In
addition, differences have been found in the
immunogenicity of particular serotypes (12,13). These
are major problems in the development of effective
vaccines against pneumonic pasteurellosis. The aim of this
study was to compare the ability to produce protective
immunity of Pasteurella haemolytica serotypes to be
included in different vaccine preparations for ovine
pneumonic pasteurellosis.

two times with a 15 day interval. Two weeks after the
last injection, sera were obtained from rabbits and stored
at –20°C until used.

Materials and Methods

Group 5. Combined monovalent immunogen of
serotype A2.

P. haemolytica Strains and Serotypes
P. haemolytica serotype A1, A2, A7, T4 and A6
strains used in the study were selected from 52 P.
haemolytica isolates from pneumonic ovine lungs,
described elsewhere (3). Isolates were identified and
biotyped according to their phenotypical characteristics
(2). Serotyping of P. haemolytica strains was performed
by an indirect hemagglutination test (2). Representative
strains of 16 P. haemolytica serotypes were kindly
provided by Dr. Sanchis (CNEVA, Unite Petits Ruminants,
France) and Dr. Fodor (Department of Epizootiology,
University of Veterinary Science, Hungary).
Production of Immunogens
Immunogens were prepared using P. haemolytica
serotype A1, A2, A7 and T4 isolates. To produce
bacterins, 24 h Brain Heart Infusion (BHI) agar cultures
of selected strains were collected in PBS and washed
three times. Cell suspension was adjusted to 109 cfu/ml in
PBS and formalin was added to give a final concentration
of 0.3%.
To produce leukotoxin, selected strains were cultured
in 250 ml of BHI broth by shaking for 4 h and
centrifugated. Supernatant was filtered through 0.2 µm
membrane filter and dialyzed in a cellulose dialysis tube
(Sigma, D9652) against distilled water overnight.
Resultant fluid was stored at -70°C and used as
leukotoxin.
To prepare combined immunogens, whole cell bacterin
was pelleted by centrifugation and suspended in
leukotoxin fluid to give 109 cell/ml.
Immunization of Rabbits
The following monovalent and polyvalent
immunogens in one ml were administered intramuscularly
to seven groups of New Zealand white rabbits (n=2-4),
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Group 1. Polyvalent bacterin, containing serotype A1,
A2, A7 and T4 bacterins pooled in equal volumes.
Group 2. Polyvalent leukotoxin, containing serotype
A1, A2, A7 and T4 leukotoxins pooled in equal volumes.
Group 3. Combined polyvalent immunogen,
containing serotype A1, A2, A7 and T4 combined
immunogens pooled in equal volumes.
Group 4. Combined monovalent immunogen of
serotype A1.

Group 6. Combined monovalent immunogen of
serotype A7.
Group 7. Combined monovalent immunogen of
serotype T4.
Measurement of Serum IgG Levels
Serum IgG levels of immunized rabbits were
measured by ELISA. In ELISA, sera from each
immunization group were tested with whole cell antigens
of A1, A2, A7 and T4 serotypes. Anti-rabbit IgG
peroxidase conjugate (Sigma, A1949) and Ophenylendiamine (Sigma, P8287) plus H2O2 substrate
were used in the test. The reaction was measured in an
ELISA reader. Sera collected from each group prior to
immunization were used as negative controls.
Measurement of Serum Anti-Leukotoxin Activity
Peripheral blood neutrophils to be used in the
leukotoxin assay were prepared using a previously
described method (14). The leukotoxin activity of P.
haemolytica strains was detected by trypan blue dye
exclusion assay (15). In short, two-fold serial dilutions of
leukotoxin preparations of serotypes A1, A2, A7 and T4
were added to equal volumes of neutrophil cell
suspensions (105 cell/ml). After 3 h incubation at 37°C,
an equal volume of 0.4% trypan blue dye solution was
added and cell viability was assayed microscopically within
30 min. To measure anti-leukotoxin levels of immune
sera, sera of each group were diluted two-fold and mixed
with an equal volume of leukotoxin preparations from
each serotype. After 15 min of incubation, trypan blue
dye exclusion test was performed and the dilution causing
50% toxin neutralization was determined. Sera collected
from each group prior to immunization were used as
negative controls.
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Passive Protection of Mice
The protective ability of immune sera against P.
haemolytica challenge was investigated in Swiss albino
mice. P. haemolytica A1, A2, A7, T4 and A6 serotypes
were used as challenge strains. To determine the MLD50
dose, serial ten-fold dilutions were prepared from BHI
culture of each strain, and 0.2 ml of each dilution was
given intraperitoneally (i.p) to mice.
To determine the protective ability of rabbit immune
sera, 0.5 ml of sera from groups 1, 2 and 3 were
injected to three groups of mice intraperitoneally, each
consisting of 30 mice. Five hours after injection, 6 mice
from each group were challenged with 10 x MLD50 of P.
haemolytica serotypes in 0.2 ml. The deaths within 24-72
h were recorded.
Results
Serum IgG levels of seven groups of rabbits
immunized with various preparations are shown in Table
1. The highest IgG levels against A1, A2, A7 and T4
antigens were detected in group 3 rabbits receiving
polyvalent combined immunogens. In polyvalent
immunogen groups, the lowest IgG levels were detected
in leukotoxin-immunized ones. Monovalent combined

immunogens induced high antibody titers against
homologous serotypes, but low titers against
heterologous serotypes. Serotype A1 and A7 were found
to be more antigenic than A2 and T4. The IgG titers of
rabbit sera prior to immunization were 1:2 or less.
Antileukotoxin activity of rabbit sera immunized with
various preparations are shown in Table 2. Sera of rabbits
immunized with leukotoxin-containing preparations
(groups 2-7) showed more antileukotoxin activity than
those that received bacterin (group 1). In monovalent
groups, the highest antileukotoxin activity was detected
in A7 and A1 antisera. Antileukotoxic activity of A1 and
A7 sera against cross-serotype was also high. No
antileukotoxin activity was detected in rabbit sera prior to
immunization.
The protective ability of polyvalent immune sera in
mice infected with challenge strains is shown in Table 3.
The highest protection was detected in mice treated with
antisera against polyvalent combined immunogen.
Antisera against polyvalent combined immunogen
protected 83-100% of mice against A1, A7 and T4
challenge, and 50% of mice against A2 challenge. The
lowest protection (16-33%) was seen in serotype A6
infected mice, as heterologous challenge.

Table 1.

Serum IgG titers of
immunization groups of
rabbits to P. haemolytica.
Serotype A1, A2, A7 and
T4 antigens were used in
ELISA.

Table 2.

Serum
anti-leukotoxin
titers of immunization
groups of rabbits. Serotype
A1, A2, A7 and T4
leukotoxins were used in
toxin-neutralization test.

Antigen
Rabbits

Serotype A1

Serotype A2

Serotype A7

Serotype T4

Group
Group
Group
Group
Group
Group
Group

1:256-512
1:128-512
1:128-512
1:1024
1:4-8
1:128
1:8-16

1:32-128
1:32-64
1:256-512
1:8-16
1:256-512
1:8
1:4-16

1:256-1024
1:128-512
1:512-1024
1:64-128
1:4-16
1:1024-2048
1:16-32

1:128-512
1:128-256
1:256-512
1:8
1:4-8
1:64
1:256-512

Rabbits

Serotype A1

Serotype A2

Serotype A7

Serotype T4

Group
Group
Group
Group
Group
Group
Group

1:16-32
1:128-256
1:128-256
1:256
1:2-4
1:128
1:4

1:4-16
1:64-128
1:16-32
1:4
1:128
1:4
1:2

1:32-64
1:256-1028
1:256-512
1:128
1:4
1:512
1:2

1:4-16
1:64-128
1:64-128
1:2-4
1:2
1:2
1:128

1
2
3
4
5
6
7

1
2
3
4
5
6
7
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Table 3.
Challenge
strain
dose
A1
A2
A7
T4
A6

2.0x107
2.0x106
2.0x107
2.0x108
2.0x107

Group 1
death protection
2/6
4/6
2/6
1/6
5/6

66%
33%
66%
83%
16%

Source of antiserum
Group 2
Group3
death
protection
death protection
4/6
5/6
4/6
3/6
5/6

33%
16%
33%
50%
16%

Discussion

P. haemolytica is the organism most commonly
associated with ovine pneumonia in Turkey (1). Various
serotypes may be involved, but serotypes A2, A1, A7 and
T4 are more frequently isolated from the cases in Turkey,
at least in central Anatolia (3,4). Despite intense efforts
to treat and control the infection using antimicrobial
drugs (16) and immunoprophylactic methods (7), P.
haemolytica continues to be an important pathogen in
sheep. A major problem in the control of ovine pneumonic
pasteurellosis is the lack of a vaccine, that consistently
induces protective immunity. Although a number of live
and killed vaccines have been developed and used, their
efficacy in field trials have been variable, ranging from no
effect to reduced or even increased morbidity and
mortality (7,9). These facts lead us to investigate the
immunogenicity of common serotypes and the
effectiveness of several formulations of immunogens in
laboratory test systems.
P. haemolytica possesses a number of characteristics
that should be taken into account when the production
and formulation of a vaccine are contemplated. We chose
the whole cell, which contains most of the potential
antigens, and leukotoxin, which is the most important
virulence factor in the pathogenesis of disease, for
immunogen in this experiment.
Differences were observed in the immunogenicity of
whole cell preparations of P. haemolytica serotypes used
in this study. Relatively low antibody titers against
serotypes A2 and T4 were remarkable. Several
researchers have also reported antigenic differences
among serotypes (8)
and pointed out the low
immunogenicity of serotype 2 (9). Jones et al. (9) have
shown that A2 serotype was poorly immunogenic in
lambs, mice and rabbits. The immunogenicity of
leukotoxin was associated with its activity on target cells,
except serotype A2. Although A2 had the most potent
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1/6
3/6
1/6
0/6
4/6

83%
50%
83%
100
33

Passive protection of mice
by immune sera from three
immunization
groups.
Each challenge group
contained
six
mice.
Challange doses show 10
X MLD50.

leukotoxin activity, its immunogenicity was relatively low.
Burrows et al. (17) have found at least seven different
variations of leukotoxin determinants among 16
serotypes of P. haemolytica. This means that leukotoxins
produced by P. haemolytica serotypes are not completely
identical, and may explain the differences in the
immunogenicity of leukotoxins from different serotypes.
A low degree of cross-reaction was detected among
different serotypes used in this study and was evident in
both whole cell and leukotoxin preparations. This was not
surprising for whole cell immunogens, since differences in
surface antigens are the basis of serotypes (2). Shewen
and Wilkie (18) have reported that neutralization of toxin
by type-specific antisera is more effective than that of
heterologous antisera.
We performed challenge experiments in mice as a lowcost alternative model, since mice have been used as
experimental animal in protection studies of P.
haemolytica (19,20). Jones et al. (21) used passively
transferred immune serum to protect experimentally
infected lambs and concluded that systemic humoral
immunity alone can prevent pneumonic pasteurellosis. In
our study, serum IgG levels appeared to be related to
protection, except serotype T4. The reason for this
contradictory finding with T4 could not be explained
properly, but it was assumed that a different mechanism
might be involved in the in vivo susceptibility of serotype
T4 to immune sera. Among three groups of immune sera,
sera against polyvalent combined immunogen achieved
the highest protection to all challenge serotypes.
Sutherland et al. (10) have reported that cytotoxin is an
essential component of a protective vaccine and
protection correlates with cytotoxin-neutralising titer of
serum. In our study, injected immunoglobulins may have
been bactericidal with complement, and/or neutralized
metabolic function or products.

K. S. DİKER, M. AKAN, O. KAYA

The low degree of cross-protection among different
serotypes was evident in mice challenged with serotype
A6. Since immunogens did not contain serotype A6, none
of the immune sera gave passive protection in mice
challenged with this serotype. Purdy et al. (13) observed
a limited degree of cross-protection against heterologous
serotypes in an experimental goat model. Chandrasekaran
et al. (22) have reported that vaccine containing local
strains was more effective than imported commercial
vaccine to prevent pneumonic pasteurellosis.

In conclusion, marked differences in the
immunogenicity of particular serotypes and the limited
protection against heterologous serotypes may cause
vaccine failures. For these reasons, to control ovine
pneumonic pasteurellosis, the prevalence of the different
local serotypes should be continually monitored, and the
pathogenicity and immunogenicity of new serotypes
should be investigated, so that the appropriate strains can
be incorporated in the vaccine.
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